Technology Neutral

Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million

Breaking news from global financial markets

il y a 4 semaines
Lire Plus